Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics

Abstract

We recently reviewed the status of peptide and nonpeptide agonists and antagonists for the V 1a , V 1b and V 2 receptors for arginine vasopressin (AVP) and the oxytocin receptor for oxytocin (OT). In the present review, we update the status of peptides and nonpeptides as: (i) research tools and (ii) therapeutic agents. We also present our recent findings on the design of fluorescent ligands for V 1b receptor localisation and for OT receptor dimerisation. We note the exciting discoveries regarding two novel naturally occurring analogues of OT. Recent reports of a selective VP V 1a agonist and a selective OT agonist point to the continued therapeutic potential of peptides in this field. To date, only two nonpeptides, the V 2 /V 1a antagonist, conivaptan and the V 2 antagonist tolvaptan have received Food and Drug Administration approval for clinical use. The development of nonpeptide AVP V 1a , V 1b and V 2 antagonists and OT agonists and antagonists has recently been abandoned by Merck, Sanofi and Pfizer. A promising OT antagonist, Retosiban, developed at Glaxo SmithKline is currently in a Phase II clinical trial for the prevention of premature labour. A number of the nonpeptide ligands that were not successful in clinical trials are proving to be valuable as research tools. Peptide agonists and antagonists continue to be very widely used as research tools in this field. In this regard, we present receptor data on some of the most widely used peptide and nonpeptide ligands, as a guide for their use, especially with regard to receptor selectivity and species differences.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 246

1. 1.

   Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G, Landgraf R, Neumann I. Peptide and Nonpeptide Agonists and Antagonists for the Vasopressin and Oxytocin V1a, V1b, V2 and OT Receptors: Research Tools and Potential Therapeutic Agents. 2008;473-512.

   Not in our library10.1016/s0079-6123(08)00437-8

2. 2.

   du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG. The synthesis of oxytocin. J Am Chem Soc. 1954;76:3115-3121.

   Not in our library

3. 3.

   du Vigneaud V, Gish DT, Katsoyannis PG. A synthetic preparation possessing biological properties associated with arginine-vasopressin. J Am Chem Soc. 1954;76:4751-4752.

   Not in our library

4. 4.

   Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963;85:2149-2154.

   Not in our library

5. 5.

   Manning M. Impact of the Merrifield solid phase method on the design and synthesis of selective agonists and antagonists of oxytocin and vasopressin: a historical perspective. Biopolymers. 2008;90:203-212.

   Not in our library10.1002/bip.20802

6. 6.

   Sawyer WH, Manning M. Synthetic analogues of oxytocin and vasopressin. Annual Rev Pharmacol. 1973;13:5-17.

   Not in our library10.1146/annurev.pa.13.040173.000253

7. 7.

   Manning M, Grzonka Z, Sawyer WH, Beardwell C, Robertson G. Synthesis of posterior pituitary hormones and hormone analogues. The Pituitary. 1981;265-296.

   Not in our library

8. 8.

   Sawyer WH, Grzonka Z, Manning M. Neurohypophyseal peptides: design of tissue-specific agonists and antagonists. Mol Cell Endocrinol. 1981;22:117-134.

   Not in our library10.1016/0303-7207(81)90086-1

9. 9.

   Manning M, Sawyer WH, Schrier R. Development of Selective Agonists and Antagonists of Vasopressin and Oxytocin, Vasopressin. 1985;131-144.

   Not in our library

10. 10.

    Manning M, Bankowski K, Sawyer WH, Gash DM, Boer GJ. Selective agonists and antagonists of vasopressin. Vasopressin: Principles and Properties. 1987;335-368.

    Not in our library

11. 11.

    Manning M, Sawyer WH. Discovery, development, and some uses of vasopressin and oxytocin antagonists. J Lab Clin Med. 1989;114:617-632.

    Not in our library

12. 12.

    Barberis C, Morin D, Durroux T, Mouillac B, Guillon G, Hibert M, Tribollet E, Manning M. Molecular pharmacology of vasopressin and oxytocin receptors and therapeutic potential. Manning. Drug News Perspect. 1999;12:279-292.

    Not in our library

13. 13.

    Manning M, Sawyer WH. Design, synthesis and some uses of receptor specific agonists and antagonists of vasopressin and oxytocin. J Receptor Res. 1993;13:195-214.

    Not in our library10.3109/10799899309073655

14. 14.

    Manning M, Sawyer WH, Jard S, Jamison R. Antagonists of vasopressin and oxytocin: current status and future perspectives. Vasopressin. 1991;297-309.

    Not in our library

15. 15.

    Chan WY, Wo NC, Stoev S, Cheng LL, Manning M. Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays. Exp Physiol. 2000;85(Suppl):7S-18S.

    Not in our library10.1111/j.1469-445x.2000.tb00003.x

16. 16.

    Manning M, Flegel M, Fritkin M, Gilon C, Slaninova S. Neurohypophyseal peptide agonists and antagonists: a five decade trail from du Vigneaud to 2004. Peptides 2004. 2005;101-106.

    Not in our library

17. 17.

    Berde B, Boissonnas RA, Berde B. Basic pharmacological properties of synthetic analogues and homologues of the neurohypophysial hormones. Neurohypophysial Hormones and Similar Polypeptides, Handbook of Experimental Pharmacology 23. 1968;802-870.

    Not in our library

18. 18.

    Lebl M, Jost K, Lebl M, Brtnik F. Analogs with inhibitory properties. Handbook of Neurohypophyseal Hormone Analogs. 1988;2:17-72.

    Not in our library

19. 19.

    Pierzynski P. Oxytocin and vasopressin V1a receptors as new therapeutic targets in assisted reproduction. Reprod Biomed Online. 2011;22:9-16.

    Not in our library10.1016/j.rbmo.2010.09.015

20. 20.

    Hruby VJ, Smith CW, Udenfriend S, Meienhofer J. Structure-activity relationships of neurohypophyseal peptides. The Peptides: Analysis, Synthesis, Biology. 1987;77-207.

    Not in our library

21. 21.

    Frank E, Landgraf R. The vasopressin system – from antidiuresis to psychopathology. Eur J Pharmacol. 2008;583:226-242.

    Not in our library10.1016/j.ejphar.2007.11.063

22. 22.

    Jard S, Zingg HH, Bourque CW, Bichet DG. Vasopressin receptors. A historical survey. Adv Exp Med Biol. 1998;1-13.

    Not in our library

23. 23.

    Gimpl G, Fahrenholz F. The oxytocin receptor system: structure function and regulation. Physiol Rev. 2001;81:629-683.

    Not in our library10.1152/physrev.2001.81.2.629

24. 24.

    Insel TR, Young LJ. The neurobiology of attachment. Nat Rev Neurosci. 2001;2:129-136.

    Not in our library10.1038/35053579

25. 25.

    Bosch OJ, Meddle SL, Beiderbeck DI, Douglas AJ, Neumann ID. Brain oxytocin correlates with maternal aggression: link to anxiety. J Neurosci. 2005;25:6807-6815.

    Not in our library10.1523/jneurosci.1342-05.2005

26. 26.

    Huber D, Veinante P, Stoop R. Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science. 2005;308:245-248.

    Not in our library10.1126/science.1105636

27. 27.

    Ma S, Shipston MJ, Morilak D, Russell JA. Reduced hypothalamic vasopressin secretion underlies attenuated adrenocorticotropin stress responses in pregnant rats. Endocrinology. 2005;146:1626-1637.

    Not in our library10.1210/en.2004-1368

28. 28.

    Parker KJ, Buckmaster CL, Schatzberg AF, Lyons DM. Intranasal oxytocin administration attenuates the ACTH stress response in monkeys. Psychoneuroendocrinology. 2005;30:924-929.

    Not in our library10.1016/j.psyneuen.2005.04.002

29. 29.

    Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S, Gruppe H, Mattay VS, Gallhofer B, Meyer-Lindenberg A. Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci. 2005;25:11489-11493.

    Not in our library10.1523/jneurosci.3984-05.2005

30. 30.

    Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L, Anagnostou E, Wasserman S. Oxytocin increases retention of social cognition in autism. Biol Psychiatry. 2007;61:498-503.

    Not in our library10.1016/j.biopsych.2006.05.030

31. 31.

    Hollander E, Novotny S, Hanratty M, Yaffe R, DeCaria CM, Aronowitz BR, Mosovich S. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger’s disorders. Neuropsychopharmacology. 2003;28:193-198.

    Not in our library10.1038/sj.npp.1300021

32. 32.

    Harony H, Wagner S. The contribution of oxytocin and vasopressin to mammalian social behavior: potential role in autism spectrum disorder. Neurosignals. 2010;18:82-97.

    Not in our library10.1159/000321035

33. 33.

    Meyer-Lindenberg A, Domes G, Kirsch P, Heinrich M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci. 2011;12:524-538.

    Not in our library10.1038/nrn3044

34. 34.

    Striepens N, Kendrick KM, Maier W, Hurlemann R. Prosocial effects of oxytocin and clinical evidence for its therapeutic potential. Front Neuroendocrinol. 2011;32:426-450.

    Not in our library10.1016/j.yfrne.2011.07.001

35. 35.

    Ellenbogen MA, Linnen AM, Grumet R, Cardoso C, Joober R. The acute effects of intranasal oxytocin on automatic and effortful attentional shifting to emotional faces. Psychophysiology. 2012;49:128-137.

    Not in our library10.1111/j.1469-8986.2011.01278.x

36. 36.

    Ring RH. The central vasopressinergic system: examining the opportunities for psychiatric drug development. Curr Pharm Des. 2005;11:205-225.

    Not in our library10.2174/1381612053382241

37. 37.

    Grazzini E, Lodboerer AM, Perrez-Martin A, Joubert D, Guillon G. Molecular and functional characterization of V1b vasopressin receptor in rat adrenal medulla. Endocrinology. 1996;137:3906-3914.

    Not in our library10.1210/endo.137.9.8756565

38. 38.

    Wisniewski K, Galyean R, Schteingart CD, Tariga H, Croston G, Alagarsamy S, Riviere PJM, Lebl M, Meldal M, Knud J, Jensen KJ, Høeg-Jensen T. Synthesis and in vitro characterization of new potent and selective oxytocin receptor agonist. Peptides 2010. 2010;306-307.

    Not in our library

39. 39.

    Laporte R, Kohan A, Heitzmann J, Wisniewska H, Toy J, La E, Tariga H, Alagarsamy S, Ly B, Dykert J, Qi S, Wisniewski K, Galyean R, Croston G, Schteingart CD, Rivière PJ. Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension. J Pharmacol Exp Ther. 2011;337:786-796.

    Not in our library10.1124/jpet.111.178848

40. 40.

    Kwiatkowska A, Sobolewski D, Prahl A, Borovicková L, Slaninová J, Lammek B. Arginine vasopressin and its analogues-the influence of position 2 modification with 3,3-diphenylalanine enantiomers. Highly potent V2 agonists. Eur J Med Chem. 2009;44:2862-2867.

    Not in our library10.1016/j.ejmech.2008.12.010

Cited by papers we hold 3

• The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors · 2023
  No notice
• Oxytocin in the medial prefrontal cortex is involved in maternal care, maternal aggression and anxiolysis during the postpartum period · 2014
  Not checked
• Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders · 2013
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.